

Makers Laboratories Limited

Regd. Office : 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067


CIN : L24230MH1984PLC033389

Tel: +91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
I	Revenue from Operations	1,480.67	1,112.68	913.82	4,441.14
II	Other Income	5.61	6.51	21.14	41.40
III	Total Income (I + II)	1,486.28	1,119.18	934.96	4,482.54
IV	Expenses:				
	a) Cost of materials consumed	193.19	144.14	110.38	621.98
	b) Purchases of stock-in-trade	713.79	556.21	309.62	1,644.82
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(131.60)	(136.55)	(22.23)	(20.55)
	d) Employee benefits expense	225.63	206.41	194.18	763.02
	e) Finance Cost	43.30	42.30	39.56	158.90
	f) Depreciation and amortisation expense	46.19	109.15	100.10	419.58
	g) Other expenses	360.93	265.37	206.49	1,102.20
	Total Expenses (IV)	1,451.43	1,187.03	938.10	4,689.95
V	Profit / (Loss) before tax (III - IV)	34.85	(67.84)	(3.14)	(207.41)
VI	Tax Expense				
	Current Tax	-	-	-	-
	Short / Excess Provision of earlier years	-	(1.75)	-	(16.70)
	Deferred Tax (Asset) / Liability	5.29	8.67	(4.70)	(29.05)
VII	Net Profit / (Loss) after tax (V-VI)	29.56	(74.76)	1.56	(161.66)
VIII	Other Comprehensive Income				
	Items that will not be reclassified to profit & loss				
	(a) Actuarial gain and loss	(1.28)	5.62	(2.14)	(5.10)
	Tax Effect thereon	-	-	-	-
	(b) Fair Value change through Other Comprehensive Income	51.93	(13.91)	291.61	720.80
	Tax Effect thereon	(4.54)	23.32	(35.36)	(53.87)
	Other Comprehensive Income	46.11	15.03	254.11	661.83
IX	Total Comprehensive Income after tax (VII + VIII)	75.67	(59.73)	255.67	500.17
X	Paid-up equity share capital (Face value of Rs.10/- each)	491.70	491.70	491.70	491.70
XI	Other Equity				4,470.40
XII	Earnings per share (of Rs.10/- each) - Not annualised:				
	Basic & Diluted	0.60	(1.52)	0.03	(3.29)




Notes:


- 1 The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 13, 2021
- 2 The statutory auditors have carried out a limited review of the financial results and have issued their unmodified report thereon.
- 3 The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- 4 In order to align the depreciation of the entire group to straight line method(SLM), the company has changed the depreciation of assets which were hitherto depreciation on Written down value method to SLM. On account this change in the nature of estimates , the depreciation for the quarter is lower by Rs 48.07 Lacs and profit for the quarter is higher by Rs. 48.07 Lacs
- 5 The Company has carried out assessment of impact of COVID-19 on its business operations and liquidity position and has taken into account all known events arising from the pandemic in the preparation of the standalone financial results. The Company will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.
- 6 The figures for the quarter ended March 31, 2021 are the balancing figure between the Audited Figures in respect of full financial year and the reviewed year-to-date figures up to the third quarter of the financial year.
- 7 The Company has only one reportable segment viz. 'Pharmaceuticals' and as such there are no separate reportable segment as per Indian Accounting Standard "Operating Segment (Ind AS- 108)
- 8 Figures for the previous period have been regrouped / re-classified to confirm to the figures of the current period.

Place : Mumbai,
Date : August 13, 2021



By Order of the Board
For Makers Laboratories Limited


Saahil Parikh
Wholetime Director
(DIN 00400079)



Makers Laboratories Limited

Regd. Office : 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

Statement of Unaudited Consolidated Financial Results for Quarter Ended June 30, 2021

Sr. No.	Particulars	Quarter Ended		Year Ended
		June 30, 2021	March 31, 2021	March 31, 2021
		(Unaudited)	(Audited)	(Audited)
I	Revenue from Operations	3,629.09	3,095.57	6,864.11
II	Other Income	59.08	34.16	95.62
III	Total Income (I + II)	3,688.17	3,129.73	6,959.73
IV	Expenses:			
	a) Cost of materials consumed	877.39	667.53	1,447.66
	b) Purchases of stock-in-trade	713.79	556.21	1,644.82
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	54.00	(135.00)	(176.48)
	d) Employee benefits expense	310.02	292.09	870.54
	e) Finance Cost	43.30	57.85	175.10
	f) Depreciation and amortisation expense	99.74	142.98	461.07
	g) Other expenses	1,097.70	1,251.70	2,266.55
	Total Expenses (IV)	3,195.94	2,833.36	6,689.26
V	Profit / (Loss) before tax (III - IV)	492.23	296.37	270.47
VI	Tax Expense			
	Current Tax	116.20	100.33	136.75
	Short / (Excess) Provision of earlier years	-	37.73	22.78
	Deferred Tax (Asset) / Liability	3.45	9.25	(23.92)
VII	Net Profit / (Loss) after tax but before non-controlling interests (V - VI)	372.58	149.06	134.86
VIII	Less: Share of non-controlling interests	(190.96)	(126.98)	(167.78)
IX	Net Profit / (Loss) after share of non-controlling interests (VII - VIII)	181.62	22.08	(32.92)
X	Other Comprehensive Income			
	(a) Actuarial gain and loss	(8.91)	7.08	(6.09)
	Tax Effect thereon	(1.99)	0.12	(0.50)
	(b) Fair Value change through Other Comprehensive Income	51.93	(13.91)	720.80
	Tax Effect thereon	(4.54)	23.32	(53.87)
	Other Comprehensive Income / (Loss) for the period, net of tax	36.49	16.61	660.34
XI	Total Comprehensive Income after tax (VII + X)	409.07	165.67	795.20
	Other Comprehensive Income for the period attributable to :			
	Owners of the parent	41.74	15.76	661.16
	Non-controlling interest - profit / (loss)	(5.25)	0.85	(0.82)
		36.49	16.61	660.34
	Total Comprehensive Income for the period attributable to :			
	Owners of the parent	223.36	37.84	628.24
	Non-controlling interest - profit / (loss)	185.71	127.83	166.96
		409.07	165.67	795.20
X	Paid-up equity share capital (Face value of Rs.10/- each)	491.70	491.70	491.70
XI	Earnings per share (of Rs.10/- each) - Not annualised :			
	Basic & Diluted	3.69	0.45	(0.67)



Notes:

- 1 The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 13, 2021
- 2 The statutory auditors have carried out a limited review of the financial results and have issued their unmodified report thereon.
- 3 The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- 4 The acquisition of Resonance Specialties Limited has resulted in the company preparing consolidated financial statements for the first time in Dec 2020. Therefore the comparative figures for the previous quarter ended June 30, 2020 were not prepared and accordingly are not presented in the results for the quarter ended June 30, 2021.
- 5 In order to align the depreciation of the entire group to straight line method(SLM), the group has changed the depreciation of assets which were hitherto depreciation on Written down value method to SLM. On account this change in the nature of estimates , the depreciation for the quarter is lower by Rs 27.67 Lacs and profit for the quarter is higher by Rs. 27.67 Lacs
- 6 The Group has carried out assessment of impact of COVID-19 on its business operations and liquidity position and has taken into account all known events arising from the pandemic in the preparation of the consolidated financial results. The group will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.
- 7 The figures for the quarter ended March 31, 2021 are the balancing figure between the Audited Figures in respect of full financial year and the reviewed year-to-date figures up to the third quarter of the financial year.
- 8 Pursuant to acquisition of Resonance, the group has two reportable segments viz. "Pharmaceutical" and " Chemical Manufacturing" as per Indian Accounting Standard "Operating Segment (Ind AS- 108). Segment information is given here in below

Particulars	Quarter Ended June 30, 2021	Quarter Ended March 31, 2021	Year Ended March 31, 2021
Segment Revenue			
- Pharmaceutical	1,485.50	1,117.73	4,480.92
- Chemical Manufacturing	2,202.67	2,012.00	2,478.81
Segment Results - PBT			
- Pharmaceutical	34.11	(68.52)	(208.26)
- Chemical Manufacturing	458.12	364.89	478.73
Total PBT	492.23	296.37	270.47
Segment Assets			
- Pharmaceutical	5,969.48	5,667.18	5,667.18
- Chemical Manufacturing	7,871.51	7,952.09	7,952.09
Segment Liabilities			
- Pharmaceutical	3,175.61	2,947.00	2,947.00
- Chemical Manufacturing	1,599.13	2,015.05	2,015.05

- 9 Figures for the previous period have been regrouped / re-classified to confirm to the figures of the current period's classification.



By Order of the Board
For Makers Laboratories Limited

Saahil Parikh
Saahil Parikh
Wholetime Director
(DIN 00400079)

Place : Mumbai,
Date : August 13, 2021

